Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) has received a consensus recommendation of “Buy” from the fourteen analysts that are covering the company. Five equities research analysts have rated the stock with a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $39.91.

Several equities analysts recently weighed in on ACAD shares. Goldman Sachs Group Inc. started coverage on shares of Acadia Pharmaceuticals in a research report on Friday, November 11th. They set a “neutral” rating and a $28.00 price target for the company. Cowen and Company restated an “outperform” rating and set a $42.00 price target on shares of Acadia Pharmaceuticals in a research report on Thursday, November 10th. Leerink Swann restated a “hold” rating and set a $29.00 price target on shares of Acadia Pharmaceuticals in a research report on Tuesday, November 8th. Bank of America Corp. upgraded shares of Acadia Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $35.00 price target for the company in a research report on Tuesday, November 8th. They noted that the move was a valuation call. Finally, Needham & Company LLC restated a “buy” rating and set a $49.00 price target on shares of Acadia Pharmaceuticals in a research report on Monday, October 24th.

Acadia Pharmaceuticals (NASDAQ:ACAD) traded up 2.99% during trading on Wednesday, reaching $27.52. 1,115,001 shares of the company’s stock traded hands. Acadia Pharmaceuticals has a 52-week low of $16.64 and a 52-week high of $42.49. The stock’s market cap is $3.33 billion. The company’s 50 day moving average is $25.72 and its 200-day moving average is $31.95.

Acadia Pharmaceuticals (NASDAQ:ACAD) last posted its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by $0.05. Acadia Pharmaceuticals had a negative return on equity of 58.46% and a negative net margin of 4,427.79%. The firm earned $5.30 million during the quarter, compared to the consensus estimate of $2.90 million. During the same quarter in the previous year, the company earned ($0.39) EPS. The business’s revenue was up 13489.7% compared to the same quarter last year. On average, analysts anticipate that Acadia Pharmaceuticals will post ($2.34) earnings per share for the current fiscal year.

Several large investors have recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in shares of Acadia Pharmaceuticals by 23.0% in the first quarter. Geode Capital Management LLC now owns 675,017 shares of the biopharmaceutical company’s stock worth $18,873,000 after buying an additional 126,169 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in shares of Acadia Pharmaceuticals during the first quarter worth $7,264,000. BNP Paribas Arbitrage SA increased its stake in shares of Acadia Pharmaceuticals by 32,684.1% in the second quarter. BNP Paribas Arbitrage SA now owns 20,654 shares of the biopharmaceutical company’s stock worth $670,000 after buying an additional 20,591 shares in the last quarter. CT Financial Advisors LLC increased its stake in shares of Acadia Pharmaceuticals by 35.0% in the second quarter. CT Financial Advisors LLC now owns 9,656 shares of the biopharmaceutical company’s stock worth $313,000 after buying an additional 2,505 shares in the last quarter. Finally, Hollencrest Securities LLC increased its stake in shares of Acadia Pharmaceuticals by 4.4% in the second quarter. Hollencrest Securities LLC now owns 12,602 shares of the biopharmaceutical company’s stock worth $409,000 after buying an additional 532 shares in the last quarter. 90.80% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and republished in violation of United States and international copyright and trademark law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/23/acadia-pharmaceuticals-inc-acad-receives-consensus-recommendation-of-buy-from-analysts.html.

Acadia Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP).

5 Day Chart for NASDAQ:ACAD

Receive News & Stock Ratings for Acadia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.